巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    DaVita

    DVA
    94.490
    0.200
    0.21%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・DaVita - 延遲價格・最後更新於 20/05 12:15
    最高位
    94.980
    最低位
    92.760
    開市價
    --
    前收市價
    94.290
    成交量(千)
    54.63
    成交額(百萬)
    45.57
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    8,938.75
    市盈率
    11.220
    息率
    --
    差價
    --
    52週高低
    136.480 - 92.630
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    DaVita
    證券代碼
    DVA.US
    所屬板塊
    Medical Care Facilities
    公司業務
    DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government ( primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
    發行量
    95851893
    公司總部
    2000 16th Street
    公司網址
    https://www.davita.com
    公司電郵
    ir@davita.com
    公司電話
    +1 720 631-2100
    暫無內容

    關於

    DaVita(DVA.US)所屬的行業板塊為Medical Care Facilities。
    DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government ( primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
    詳細公司背景可參考: https://www.davita.com